Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2024 | The OPTec study: evaluating outpatient step-up administration of teclistamab in pts with R/R myeloma

Robert Rifkin • 1 Jun 2024
ASCO 2024
Multiple Myeloma Antibodies Talquetamab Teclistamab Tocilizumab
OPTec

Robert Rifkin, MD, Rocky Mountain Cancer Centers, Denver, CO, presents the first results of the OPTec trial (NCT05972135), a Phase II study evaluating outpatient (OP) step-up administration of teclistamab (Tec) in patients with relapsed/refractory (R/R) multiple myeloma (MM). Prophylactic tocilizumab and corticosteroids are given to mitigate cytokine release syndrome (CRS) and neurotoxicity in patients and make OP administration of bispecific antibodies safe and feasible. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Robert Rifkin

MM-6 study: in-class transition to a regimen of ixazomib, lenalidomide, & dexamethasone for myeloma 1:24
MM-6 study: in-class transition to a regimen of ixazomib, lenalidomide, & dexamethasone for myeloma
Robert Rifkin • 1 Jun 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals